Opthea Ltd OPT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:05 PM EDT
3.50quote price arrow down-0.08 (-2.23%)
Volume
188
Close
3.58quote price arrow down-0.03 (-0.83%)
Volume
24,303
52 week range
1.60 - 4.40
Loading...
  • Open3.61
  • Day High3.63
  • Day Low3.51
  • Prev Close3.61
  • 52 Week High4.40
  • 52 Week High Date04/01/24
  • 52 Week Low1.60
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap296.607M
  • Shares Out82.85M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta0.63
  • YTD % Change21.36

KEY STATS

  • Open3.61
  • Day High3.63
  • Day Low3.51
  • Prev Close3.61
  • 52 Week High4.40
  • 52 Week High Date04/01/24
  • 52 Week Low1.60
  • 52 Week Low Date10/27/23
  • Market Cap296.607M
  • Shares Out82.85M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta0.63
  • YTD % Change21.36

RATIOS/PROFITABILITY

  • EPS (TTM)-2.48
  • P/E (TTM)-1.44
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-165.133M
  • ROE (TTM)-3,383.08%
  • Revenue (TTM)117,100.00
  • Gross Margin (TTM)-99.74%
  • Net Margin (TTM)-138,008.09%
  • Debt To Equity (MRQ)-385.61%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Opthea Ltd

 

Profile

MORE
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A...
Jeremy Levin Ph.D.
Non-Executive Independent Chairman of the Board
Frederic Guerard Pharm.D.
Chief Executive Officer
Peter Lang
Chief Financial Officer
Mark O'neill
Vice President - Chemistry, Manufacturing and Controls
John Han Pharm.D.
Vice President - Medical Affairs
Karen Adams CPA
Vice President - Finance, Company Secretary
Address
Suite 0403
Level 4, 650 Chapel Street, South Yarra
Melbourne, VIC
3141
Australia

Top Peers

SYMBOLLASTCHG%CHG
VSTM
Verastem Inc
13.12-0.04-0.30%
VTYX
Ventyx Biosciences Inc
4.19+0.02+0.48%
ATAI
ATAI Life Sciences NV
2.05+0.14+7.33%
INZY
Inozyme Pharma Inc
4.67+0.04+0.86%
ERAS
Erasca Inc
1.89+0.03+1.61%